These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 23176057)

  • 1. In vivo delivery aspects of miRNA, shRNA and siRNA.
    Khatri N; Rathi M; Baradia D; Trehan S; Misra A
    Crit Rev Ther Drug Carrier Syst; 2012; 29(6):487-527. PubMed ID: 23176057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.
    Singh S; Narang AS; Mahato RI
    Pharm Res; 2011 Dec; 28(12):2996-3015. PubMed ID: 22033880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are Viral Vectors Any Good for RNAi Antiviral Therapy?
    Lundstrom K
    Viruses; 2020 Oct; 12(10):. PubMed ID: 33092124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo application of RNA interference: from functional genomics to therapeutics.
    Lu PY; Xie F; Woodle MC
    Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNAi in clinical studies.
    Kubowicz P; Żelaszczyk D; Pękala E
    Curr Med Chem; 2013; 20(14):1801-16. PubMed ID: 23432579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
    Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
    Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors.
    Wang H; Jiang Y; Peng H; Chen Y; Zhu P; Huang Y
    Adv Drug Deliv Rev; 2015 Jan; 81():142-60. PubMed ID: 25450259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA interference and cancer therapy.
    Wang Z; Rao DD; Senzer N; Nemunaitis J
    Pharm Res; 2011 Dec; 28(12):2983-95. PubMed ID: 22009588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miRNA cassettes in viral vectors: problems and solutions.
    Liu YP; Berkhout B
    Biochim Biophys Acta; 2011; 1809(11-12):732-45. PubMed ID: 21679781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properties of gene knockdown system by vector-based siRNA in zebrafish.
    Shinya M; Kobayashi K; Masuda A; Tokumoto M; Ozaki Y; Saito K; Kawasaki T; Sado Y; Sakai N
    Dev Growth Differ; 2013 Dec; 55(9):755-65. PubMed ID: 24117364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleic Acid Delivery System by the Combination of Lipid bubbles and Ultrasound.
    Endo-Takahashi Y; Maruyama K; Negishi Y
    Curr Pharm Des; 2018; 24(23):2673-2677. PubMed ID: 30084324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.
    Li SD; Huang L
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1317-23. PubMed ID: 19037838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA interference-based therapy and its delivery systems.
    Chen X; Mangala LS; Rodriguez-Aguayo C; Kong X; Lopez-Berestein G; Sood AK
    Cancer Metastasis Rev; 2018 Mar; 37(1):107-124. PubMed ID: 29243000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TransKingdom RNA interference: a bacterial approach to challenges in RNAi therapy and delivery.
    Keates AC; Fruehauf J; Xiang S; Li CJ
    Biotechnol Genet Eng Rev; 2008; 25():113-27. PubMed ID: 21412352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of shRNA and miRNA for Delivery to the CNS.
    Toro Cabrera G; Mueller C
    Methods Mol Biol; 2016; 1382():67-80. PubMed ID: 26611579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cationic lipids and polymers mediated vectors for delivery of siRNA.
    Zhang S; Zhao B; Jiang H; Wang B; Ma B
    J Control Release; 2007 Oct; 123(1):1-10. PubMed ID: 17716771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of RNA interference against cancer.
    Takeshita F; Ochiya T
    Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNAi-based therapeutics and tumor targeted delivery in cancer.
    Kara G; Calin GA; Ozpolat B
    Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA Interference Nanotherapeutics for Treatment of Glioblastoma Multiforme.
    Singh P; Singh A; Shah S; Vataliya J; Mittal A; Chitkara D
    Mol Pharm; 2020 Nov; 17(11):4040-4066. PubMed ID: 32902291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.